Risk of central nervous system versus systemic relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP: What should we focus on?
Status PubMed-not-MEDLINE Jazyk angličtina Země Spojené státy americké Médium electronic-ecollection
Typ dokumentu dopisy
PubMed
40933274
PubMed Central
PMC12417966
DOI
10.1002/hem3.70201
PII: HEM370201
Knihovny.cz E-zdroje
Zobrazit více v PubMed
Komrokji RS, Al Ali NH, Beg MS, et al. Outcome of diffuse large B‐cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk. 2011;11(3):257‐260. PubMed
Issa DE, van de Schans SAM, Chamuleau MED, et al. Trends in incidence, treatment and survival of aggressive B‐cell lymphoma in the Netherlands 1989‐2010. Haematologica. 2015;100(4):525‐533. PubMed PMC
International Non‐Hodgkin's Lymphoma Prognostic Factors P . A predictive model for aggressive non‐Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987‐994. PubMed
Ziepert M, Hasenclever D, Kuhnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B‐cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373‐2380. PubMed
Schmitz N, Zeynalova S, Nickelsen M, et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B‐cell lymphoma treated with R‐CHOP. J Clin Oncol. 2016;34(26):3150‐3156. PubMed
El‐Galaly TC, Villa D, Michaelsen TY, et al. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B‐cell lymphoma: an international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer. 2017;75:195‐203. PubMed
Klanova M, Sehn LH, Bence‐Bruckler I, et al. Integration of cell of origin into the clinical CNS international prognostic index improves CNS relapse prediction in DLBCL. Blood. 2019;133(9):919‐926. PubMed PMC
Savage KJ, Zeynalova S, Kansara RR, et al. Validation of a prognostic model to assess the risk of CNS disease in patients with aggressive B‐cell lymphoma. Blood. 2014;124(21):394.
Lewis KL, Jakobsen LH, Villa D, et al. High‐dose methotrexate as CNS prophylaxis in high‐risk aggressive B‐cell lymphoma. J Clin Oncol. 2023;41(35):5376‐5387. PubMed
Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP‐14) with or without rituximab: an analysis of patients treated in the RICOVER‐60 trial of the German High‐Grade Non‐Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896‐3902. PubMed
Eyre TA, Kirkwood AA, Wolf J, et al. Stand‐alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R‐CHOP and is associated increased infection‐related toxicity. Br J Haematol. 2019;187(2):185‐194. PubMed
Bobillo S, Joffe E, Sermer D, et al. Prophylaxis with intrathecal or high‐dose methotrexate in diffuse large B‐cell lymphoma and high risk of CNS relapse. Blood Cancer J. 2021;11(6):113. PubMed PMC
Puckrin R, El Darsa H, Ghosh S, Peters A, Owen C, Stewart D. Ineffectiveness of high‐dose methotrexate for prevention of CNS relapse in diffuse large B‐cell lymphoma. Am J Hematol. 2021;96(7):764‐771. PubMed
Jeong H, Cho H, Kim H, et al. Efficacy and safety of prophylactic high‐dose MTX in high‐risk DLBCL: a treatment intent‐based analysis. Blood Adv. 2021;5(8):2142‐2152. PubMed PMC
Wilson MR, Eyre TA, Kirkwood AA, et al. Timing of high‐dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood. 2022;139(16):2499‐2511. PubMed
Orellana‐Noia VM, Reed DR, McCook AA, et al. Single‐route CNS prophylaxis for aggressive non‐Hodgkin lymphomas: real‐world outcomes from 21 US academic institutions. Blood. 2022;139(3):413‐423. PubMed PMC
